Related Experiment Videos
Homocysteine and coronary risk
1Desk F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Insights
High homocysteine levels are a risk factor for coronary artery disease. Folic acid may help lower homocysteine and reduce this risk, with ongoing studies investigating its therapeutic potential.
Area of Science:
- Cardiovascular Medicine
- Nutritional Biochemistry
Background:
- Hyperhomocysteinemia is increasingly recognized as a significant risk factor in coronary artery disease (CAD) pathogenesis.
- Plasma homocysteine levels are influenced by diverse genetic and non-genetic factors.
- The precise mechanisms linking hyperhomocysteinemia to atherosclerosis remain under investigation, though potential adverse effects on vascular endothelium are noted.
Purpose of the Study:
- To explore the role of hyperhomocysteinemia as a risk factor in coronary artery disease.
- To investigate the potential of folic acid in ameliorating the adverse effects of elevated homocysteine.
- To summarize current research on homocysteine-lowering therapy with folic acid for atherosclerotic vascular disease risk.
Main Methods:
- Review of existing literature on homocysteine metabolism and cardiovascular risk.
- Analysis of studies investigating the impact of folic acid on plasma homocysteine levels.
- Examination of epidemiological and clinical trial data related to homocysteine-lowering therapy.
Main Results:
- Hyperhomocysteinemia is associated with an increased risk of atherosclerotic vascular disease.
- Folic acid, even in low doses, demonstrates potential in reducing homocysteine levels.
- Ongoing research aims to confirm the efficacy of folic acid therapy in mitigating cardiovascular events.
Conclusions:
- Hyperhomocysteinemia represents a modifiable risk factor for coronary artery disease.
- Folic acid supplementation shows promise as a therapeutic strategy to lower homocysteine and potentially reduce vascular disease risk.
- Further clinical studies are warranted to establish definitive treatment guidelines.
Abstract:
Hyperhomocysteinemia has recently emerged as a potentially major risk factor in the pathogenesis of coronary artery disease. Various genetic and nongenetic factors influence plasma homocysteine status. The mechanism associating hyperhomocysteinemia with atherosclerosis, if any, is still unclear, but homocysteine may have an adverse effect on vascular endothelium. Folic acid in low doses may ameliorate this process. Several studies are examining the influence of homocysteine-lowering therapy with folic acid on the risk of atherosclerotic vascular disease.